Table I.
Characteristics of bladder cancer patients (n=65).
| Variable | Value |
|---|---|
| Gender, n (%) | |
| Female | 10 (15.4) |
| Male | 55 (84.6) |
| Tumor stage, n (%) | |
| T2 | 22 (33.9) |
| T3 | 35 (53.8) |
| T4 | 8 (12.3) |
| Pathological type, n (%) | |
| Transitional cell carcinoma | 49 (75.4) |
| Squamous cell carcinoma | 16 (24.6) |
| Bilharzial status and grade, n (%) | |
| NB-LG | 19 (29.2) |
| B-LG | 11 (16.9) |
| NB-HG | 17 (26.2) |
| B-HG | 18 (27.7) |
| Laboratory tumor markers (mean ± SD) | |
| OPG (pg/ml) | 211.5±80.8 |
| p53 (µg/ml) | 27.3±11.6 |
| Telomerase (µg protein/assay) | 13.9±6.2 |
| Treatment modality, n (%) | |
| Total cystectomy and postoperative RT | 46 (70.8) |
| Trimodal therapy (TUR+chemoradiation) | 19 (29.2) |
NB-LG, non-bilharzial low grade; B-LG, bilharzial low grade; NB-HG, non-bilharzial high grade: B-HG, bilharzial high grade; SD, standard deviation; OPG, osteoprotegerin; RT, radiotherapy; TUR, transurethral resection.